Moreover, CCNB1, MAPK7, CD44, and CDC42 oncogenes have been associated with patients’ clinical outcomes in glioblastoma and it has been identified in simulation studies for druggable candidates of SJ10 [50]. This evidence concerns the gene CD44 and glioblastoma.